<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750879</url>
  </required_header>
  <id_info>
    <org_study_id>2012P002153</org_study_id>
    <secondary_id>5U19AI095261-02</secondary_id>
    <nct_id>NCT01750879</nct_id>
  </id_info>
  <brief_title>Tolerance Following Peanut Oral Immunotherapy</brief_title>
  <acronym>PNOIT2</acronym>
  <official_title>Clinical Desensitization and Tolerance Following Peanut Oral Immunotherapy and Subsequent Allergen Avoidance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The unifying objective of this project is to determine whether peanut oral immunotherapy (PN&#xD;
      OIT) induced clinical tolerance in the context of food allergy is significantly associated&#xD;
      with the expansion of a specific regulatory T cell subset (CD45RA- CD25++ FoxP3++) that is&#xD;
      thought to be inducible in the gut-associated lymphoid compartment and associated with&#xD;
      immunological tolerance.&#xD;
&#xD;
      The hypothesis of the study is that the induction of Treg cells will be associated with&#xD;
      clinical tolerance.&#xD;
&#xD;
      The investigators will measure the change from baseline of induced Treg cells as a frequency&#xD;
      of total CD4 T cells during active treatment and compare that between participants who&#xD;
      achieve significant clinical tolerance (Tolerance and Partial Tolerance Groups as defined&#xD;
      below) and those who do not (Treatment Failure Group).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Objectives:&#xD;
&#xD;
        1. To evaluate whether PN OIT induces increased tolerance, defined as a statistically&#xD;
           significant increase in the median eliciting dose (ED) from a double-blind&#xD;
           placebo-controlled food challenge (DBPCFC) before and after treatment with PN OIT and&#xD;
           after subsequent allergen avoidance.&#xD;
&#xD;
        2. To evaluate whether PN OIT induces clinical desensitization, defined as 1) a median&#xD;
           10-fold or greater increase in ED at DBPCFC before and after PN OIT treatment period 2)&#xD;
           a statistically significant higher median ED at DBPCFC following treatment period&#xD;
           between active and control treatment; and 3) a significantly lower frequency of&#xD;
           accidental ingestion reactions in active versus control treatment.&#xD;
&#xD;
        3. To evaluate the safety of PN OIT.&#xD;
&#xD;
      Mechanistic Objectives:&#xD;
&#xD;
        1. To determine whether PN OIT induces a statistically significant increase in the TCR&#xD;
           clonal diversity of Treg populations during active treatment among participants who&#xD;
           achieve increased clinical tolerance (Tolerance and Partial Tolerance Groups as defined&#xD;
           in clinical endpoints) versus the Treatment Failure Group.&#xD;
&#xD;
        2. To determine whether PN OIT suppresses mast cells by inducing a significant suppression&#xD;
           of the median ED on end-point dilution skin testing in actively treated participants by&#xD;
           the end of maintenance therapy.&#xD;
&#xD;
        3. To determine whether PN OIT suppresses basophils as defined by a 10-fold suppression of&#xD;
           peanut-specific basophil ED in actively treated participants by end of a maintenance&#xD;
           period.&#xD;
&#xD;
        4. To determine whether either mast cell or basophil suppression at the end of maintenance&#xD;
           therapy is significantly associated with clinical outcomes following avoidance.&#xD;
&#xD;
      Exploratory Objectives:&#xD;
&#xD;
        1. To describe the gene expression profiles and clonal diversity of regulatory and effector&#xD;
           T cell subsets before and after OIT to better understand the phenotype and ontogeny of&#xD;
           these subsets and potentially discover new therapeutic pathways.&#xD;
&#xD;
        2. To engineer human MHC class II tetramers on common HLA backgrounds and map T cell&#xD;
           epitopes of the dominant peanut allergens for use in validating earlier findings and for&#xD;
           future studies of peanut-specific immune responses in humans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">July 11, 2017</completion_date>
  <primary_completion_date type="Actual">July 11, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance, Partial Tolerance, or Treatment Failure</measure>
    <time_frame>Average 515 days from DBPCFC1 to DBPCFC3</time_frame>
    <description>Tolerance: Ingestion of 4430 mg of peanut protein at DBPCFC3 without symptoms.&#xD;
Partial Tolerance: ED at DBPCFC3 &lt;4430 mg but =&gt;430 mg AND &gt;10-fold more than at DBPCFC1.&#xD;
Treatment Failure - non desensitized: Failure to achieve the minimum maintenance dose (600 mg) of peanut protein by 12 months, or an ED &lt;1443 mg at DBPCFC2, or ED at DBPCFC3 &lt;443 mg OR &lt;10-fold more than at DBPCFC1.&#xD;
Treatment Failure - withdrawal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical: Tolerance</measure>
    <time_frame>630 days</time_frame>
    <description>The change in median eliciting dose (ED) from DBPCFC1 to DBPCFC3. (note: ED right censored to maximum dose for those without any clinical reactivity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Desensitization</measure>
    <time_frame>518 days</time_frame>
    <description>- The change in median eliciting dose (ED) from DBPCFC1 to DBPCFC2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Safety</measure>
    <time_frame>630 days</time_frame>
    <description>- The rate of reported adverse advents due to accidental ingestions in the active versus placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanistic: TCR Clonal Diversity</measure>
    <time_frame>630 days</time_frame>
    <description>The change in the TCR clonal diversity of in vitro allergen-expanded Treg cells and induced Treg cells measured by TCRB CDR3 sequence clonotyping of sorted cells during active treatment among participants who achieve increased clinical tolerance (Tolerance and Partial Tolerance Groups as defined in clinical endpoints) versus the Treatment Failure Group.&#xD;
We conducted a nested case-control analysis of a subset of actively treated (by treatment outcome) versus placebo treated patients. Genomic DNA was used to amplify and sequence the complementarity-determining region 3 (CDR3) regions (immunoSEQ assay; Adaptive Biotechnologies).&#xD;
Enriched clonotypes in the CD154+ fraction (doi: https://doi.org/10.1101/2020.05.11.088286) were analyzed for differences by Rank Abundance Curve analysis (R package alakazam; Chao A, et al. Ecology. 2015 96, 11891201) to determine differences in clonal diversity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanistic: Change Eliciting Dose of End-point Dilution.</measure>
    <time_frame>518 days</time_frame>
    <description>The change in eliciting dose of end-point dilution skin testing between actively treated and placebo treated participants following maintenance therapy and the change in ED of end-point dilution skin testing among actively treated participants following maintenance therapy and avoidance between clinical outcome groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanistic: Change in Basophil Eliciting Dose.</measure>
    <time_frame>630 days</time_frame>
    <description>The change in peanut-specific basophil ED in actively treated participants at the end of maintenance and the end of avoidance between clinical outcome groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanistic: Change in Peanut Allergen-specific IgG4</measure>
    <time_frame>518 days</time_frame>
    <description>The change in peanut allergen-specific IgG4 in actively treated participants by the end of maintenance between clinical outcome groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanistic: Significant Gene Expression Changes by Transcriptional Profiling of Regulatory and Effector T Cell Populations</measure>
    <time_frame>630 days</time_frame>
    <description>Statistically significant gene expression changes (as number of genes) by transcriptional profiling of regulatory and effector T cell populations before and after OIT between clinical outcome groups.&#xD;
Total RNA from CD154+ and CD154-CD69- T cells was used for cDNA synthesis and amplification. Libraries were prepared and sequenced to a read depth of approximately 30 million reads per sample (Illumina HiSeq) and aligned to the hg19 human reference genome with the ensemble version 75 annotation using STAR version 2.5.3a,(Dobin et al. Bioinformatics 2013) and gene expression was summarized using RSEM version 1.3.0 (Li et al. BMC Bioinform 2013). Differential expression analysis was performed using DESeq2 v 1.30.1 (R v 4.04). Significance level was set at an unadjusted P value less than .001.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Peanut Flour</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Immunotherapy with peanut flour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oat Flour</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Immunotherapy with oat flour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peanut Flour</intervention_name>
    <description>Peanut Flour</description>
    <arm_group_label>Peanut Flour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oat Flour</intervention_name>
    <description>Oat Flour</description>
    <arm_group_label>Oat Flour</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of peanut allergy by a positive skin prick test to peanut (reaction wheal at&#xD;
             least 5 mm larger than saline control) and by medical history or Serum peanut-specific&#xD;
             IgE &gt;5 kU/L at screening visit.&#xD;
&#xD;
          -  Ara h 2 specific IgE &gt;0.35 kU/L at screening visit&#xD;
&#xD;
          -  Ability to provide informed consent.&#xD;
&#xD;
          -  Males and females of all ethnic/racial groups aged 7-55 years old who are otherwise&#xD;
             healthy.&#xD;
&#xD;
          -  React to less than 443 mg of peanut protein during DBPCFC1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe anaphylaxis as defined by hypoxia (cyanosis or SpO2 &lt;92% during&#xD;
             reaction), documented hypotension (documented systolic BP &gt;30% below predicted normal&#xD;
             for sex, height, weight or from known baseline), neurological compromise (confusion,&#xD;
             loss of consciousness), or incontinence.&#xD;
&#xD;
          -  Severe or Moderate asthma as defined using the severity criteria of the current NHBLI&#xD;
             Guidelines for the Diagnosis and Management of Asthma&#xD;
             (http://www.nhlbi.nih.gov/guidelines/asthma/).&#xD;
&#xD;
          -  Poorly-controlled asthma as defined by FEV1 &lt;80% or any of the following symptoms:&#xD;
             nighttime awakening &gt;2 days/week or rescue medication use &gt;2 days / week.&#xD;
&#xD;
          -  Diagnosis of other severe or complicating medical problems, including autoimmune or&#xD;
             chronic immune inflammatory conditions or gastrointestinal inflammatory conditions,&#xD;
             including Celiac Disease, Inflammatory Bowel Disease and Eosinophilic Gastrointestinal&#xD;
             Disorders&#xD;
&#xD;
          -  Inability to cooperate with and/or perform oral food challenge procedures.&#xD;
&#xD;
          -  Primary Immune Deficiency&#xD;
&#xD;
          -  Allergy to oat confirmed by skin prick testing and history&#xD;
&#xD;
          -  Current use of beta blockers, angiotensin converting enzyme inhibitors, or monoamine&#xD;
             oxidase inhibitors&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant, planning to become pregnant, or&#xD;
             breastfeeding&#xD;
&#xD;
          -  Hemoglobin level less than 12.5 gm/dL at screening. Weight &lt;23 kg&#xD;
&#xD;
          -  Use within the past 6 months of other systemic immunomodulatory treatments including&#xD;
             allergen immunotherapy, or use of biologics with an immune target, including&#xD;
             omalizumab.&#xD;
&#xD;
          -  Past or current medical problems or findings from physical examination or laboratory&#xD;
             testing that are not listed above, which, in the opinion of the investigator, may pose&#xD;
             additional risks from participation in the study, may interfere with the participant's&#xD;
             ability to comply with study requirements or that may impact the quality or&#xD;
             interpretation of the data obtained from the study may also exclude a participant from&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne G Shreffler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <results_first_submitted>July 11, 2018</results_first_submitted>
  <results_first_submitted_qc>July 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2021</results_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Wayne G. Shreffler, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>peanut</keyword>
  <keyword>allergy</keyword>
  <keyword>food</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>tolerance</keyword>
  <keyword>desensitization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>de-identified data exported from REDCap</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>upon request within the year and without planned time limitation</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT01750879/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from a specialty clinic, college campus clinic, and community outreach (including advertisements on Boston MBTA) between May 2013 and January 2016. The first participant was enrolled in August 2013.</recruitment_details>
      <pre_assignment_details>113 screened, 72 excluded (3 Lost to follow-up pre-randomization; 8 Re-screened following protocol change; 21 Screen Fail no objective symptoms on DBPCF1; 29 Screen Fail prior to DBPCFC; and 11 Voluntary withdrawal pre-randomization)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peanut Flour</title>
          <description>Participants will be randomly assigned by study statistician to treatment or placebo groups at a ratio of 3:1 following a double-blind placebo controlled food challenge, DBPCFC1, on 2 separate days. One challenge will consist of 5 doses of peanut in increasing amounts up to a total of 443 mg of peanut protein masked in vehicle food. The second day will consist of placebo material given similarly. Participants with an eliciting dose of 443mg or less will receive daily escalating dosages of peanut flour OIT in a blinded fashion, as described in the modified rush phase, until a daily dose of 4000 mg is reached. Following treatment, a 2nd challenge will occur DBPCFC2, identical to DBPCFC1, but with additional doses of 1000 mg and 3000 mg for a cumulative dose of 4443 mg peanut protein. After 12 weeks of complete peanut avoidance, participants will undergo a third challenge, DBPCFC3, which will follow a slightly different schedule of doses for a cumulative dose of 4430 mg peanut protein.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Oat) Flour</title>
          <description>Participants in the placebo arm will follow the same protocol except they receive daily escalating dosages of placebo oat flour, and they will not participate in DBPCFC3. Following DBPCFC2, assignment will be unblinded and placebo participants will be offered open-label active treatment under a separate protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>DBPCFC2</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>DBPCFC3</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not complete per protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>Participants will be randomly assigned by study statistician to treatment or placebo groups at a ratio of 3:1 following a double-blind placebo controlled food challenge, DBPCFC1, on 2 separate days. One challenge will consist of 5 doses of peanut in increasing amounts up to a total of 443 mg of peanut protein masked in vehicle food. The second day will consist of placebo material given similarly. Participants with an eliciting dose of 443mg or less will receive daily escalating dosages of peanut flour OIT in a blinded fashion, as described in the modified rush phase, until a daily dose of 4000 mg is reached. Following treatment, a 2nd challenge will occur DBPCFC2, identical to DBPCFC1, but with additional doses of 1000 mg and 3000 mg for a cumulative dose of 4443 mg peanut protein. After 12 weeks of complete peanut avoidance, participants will undergo a third challenge, DBPCFC3, which will follow a slightly different schedule of doses for a cumulative dose of 4430 mg peanut protein.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants in the placebo arm will follow the same protocol except they receive daily escalating dosages of placebo oat flour, and they will not participate in DBPCFC3. Following DBPCFC2, assignment will be unblinded and placebo participants will be offered open-label active treatment under a separate protocol.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.5" spread="11.1"/>
                    <measurement group_id="B2" value="16.3" spread="7.2"/>
                    <measurement group_id="B3" value="19.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transgender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peanut-specific IgE</title>
          <units>kU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116" spread="156"/>
                    <measurement group_id="B2" value="97.5" spread="121"/>
                    <measurement group_id="B3" value="111.3" spread="146.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerance, Partial Tolerance, or Treatment Failure</title>
        <description>Tolerance: Ingestion of 4430 mg of peanut protein at DBPCFC3 without symptoms.&#xD;
Partial Tolerance: ED at DBPCFC3 &lt;4430 mg but =&gt;430 mg AND &gt;10-fold more than at DBPCFC1.&#xD;
Treatment Failure - non desensitized: Failure to achieve the minimum maintenance dose (600 mg) of peanut protein by 12 months, or an ED &lt;1443 mg at DBPCFC2, or ED at DBPCFC3 &lt;443 mg OR &lt;10-fold more than at DBPCFC1.&#xD;
Treatment Failure - withdrawal</description>
        <time_frame>Average 515 days from DBPCFC1 to DBPCFC3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Participants will be randomly assigned by study statistician to treatment or placebo groups at a ratio of 3:1 following a double-blind placebo controlled food challenge, DBPCFC1, on 2 separate days. One challenge will consist of 5 doses of peanut in increasing amounts up to a total of 443 mg of peanut protein masked in vehicle food. The second day will consist of placebo material given similarly. Participants with an eliciting dose of 443mg or less will receive daily escalating dosages of peanut flour OIT in a blinded fashion, as described in the modified rush phase, until a daily dose of 4000 mg is reached. Following treatment, a 2nd challenge will occur DBPCFC2, identical to DBPCFC1, but with additional doses of 1000 mg and 3000 mg for a cumulative dose of 4443 mg peanut protein. After 12 weeks of complete peanut avoidance, participants will undergo a third challenge, DBPCFC3, which will follow a slightly different schedule of doses for a cumulative dose of 4430 mg peanut protein.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in the placebo arm will follow the same protocol except they receive daily escalating dosages of placebo oat flour, and they will not participate in DBPCFC3. Following DBPCFC2, assignment will be unblinded and placebo participants will be offered open-label active treatment under a separate protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerance, Partial Tolerance, or Treatment Failure</title>
          <description>Tolerance: Ingestion of 4430 mg of peanut protein at DBPCFC3 without symptoms.&#xD;
Partial Tolerance: ED at DBPCFC3 &lt;4430 mg but =&gt;430 mg AND &gt;10-fold more than at DBPCFC1.&#xD;
Treatment Failure - non desensitized: Failure to achieve the minimum maintenance dose (600 mg) of peanut protein by 12 months, or an ED &lt;1443 mg at DBPCFC2, or ED at DBPCFC3 &lt;443 mg OR &lt;10-fold more than at DBPCFC1.&#xD;
Treatment Failure - withdrawal</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tolerance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Tolerance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Failure- non-desensitized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Failure- withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical: Tolerance</title>
        <description>The change in median eliciting dose (ED) from DBPCFC1 to DBPCFC3. (note: ED right censored to maximum dose for those without any clinical reactivity)</description>
        <time_frame>630 days</time_frame>
        <population>Per protocol, subjects were unblinded after DBPCFC2 and those on placebo were not subjected to DBPCFC3</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour</title>
            <description>Participants will be randomly assigned by study statistician to treatment or placebo groups at a ratio of 3:1 following a double-blind placebo controlled food challenge, DBPCFC1, on 2 separate days. One challenge will consist of 5 doses of peanut in increasing amounts up to a total of 443 mg of peanut protein masked in vehicle food. The second day will consist of placebo material given similarly. Participants with an eliciting dose of 443mg or less will receive daily escalating dosages of peanut flour OIT in a blinded fashion, as described in the modified rush phase, until a daily dose of 4000 mg is reached. Following treatment, a 2nd challenge will occur DBPCFC2, identical to DBPCFC1, but with additional doses of 1000 mg and 3000 mg for a cumulative dose of 4443 mg peanut protein. After 12 weeks of complete peanut avoidance, participants will undergo a third challenge, DBPCFC3, which will follow a slightly different schedule of doses for a cumulative dose of 4430 mg peanut protein.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Oat) Flour</title>
            <description>Participants in the placebo arm will follow the same protocol except they receive daily escalating dosages of placebo oat flour, and they will not participate in DBPCFC3. Following DBPCFC2, assignment will be unblinded and placebo participants will be offered open-label active treatment under a separate protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical: Tolerance</title>
          <description>The change in median eliciting dose (ED) from DBPCFC1 to DBPCFC3. (note: ED right censored to maximum dose for those without any clinical reactivity)</description>
          <population>Per protocol, subjects were unblinded after DBPCFC2 and those on placebo were not subjected to DBPCFC3</population>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4000" lower_limit="-403" upper_limit="4400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical: Desensitization</title>
        <description>- The change in median eliciting dose (ED) from DBPCFC1 to DBPCFC2.</description>
        <time_frame>518 days</time_frame>
        <population>30 active and 11 placebo had baseline challenge (DBPCFC1); 20 active and 8 placebo had first post-treatment challenge (DBPCFC2). Change in median eliciting dose restricted to the 20 and 8 who competed DBPCFC2 (i.e., per protocol)</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour</title>
            <description>Participants will be randomly assigned by study statistician to treatment or placebo groups at a ratio of 3:1 following a double-blind placebo controlled food challenge, DBPCFC1, on 2 separate days. One challenge will consist of 5 doses of peanut in increasing amounts up to a total of 443 mg of peanut protein masked in vehicle food. The second day will consist of placebo material given similarly. Participants with an eliciting dose of 443mg or less will receive daily escalating dosages of peanut flour OIT in a blinded fashion, as described in the modified rush phase, until a daily dose of 4000 mg is reached. Following treatment, a 2nd challenge will occur DBPCFC2, identical to DBPCFC1, but with additional doses of 1000 mg and 3000 mg for a cumulative dose of 4443 mg peanut protein. After 12 weeks of complete peanut avoidance, participants will undergo a third challenge, DBPCFC3, which will follow a slightly different schedule of doses for a cumulative dose of 4430 mg peanut protein.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Oat) Flour</title>
            <description>Participants in the placebo arm will follow the same protocol except they receive daily escalating dosages of placebo oat flour, and they will not participate in DBPCFC3. Following DBPCFC2, assignment will be unblinded and placebo participants will be offered open-label active treatment under a separate protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical: Desensitization</title>
          <description>- The change in median eliciting dose (ED) from DBPCFC1 to DBPCFC2.</description>
          <population>30 active and 11 placebo had baseline challenge (DBPCFC1); 20 active and 8 placebo had first post-treatment challenge (DBPCFC2). Change in median eliciting dose restricted to the 20 and 8 who competed DBPCFC2 (i.e., per protocol)</population>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4000" lower_limit="-3" upper_limit="4400"/>
                    <measurement group_id="O2" value="-65" lower_limit="-430" upper_limit="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical: Safety</title>
        <description>- The rate of reported adverse advents due to accidental ingestions in the active versus placebo groups.</description>
        <time_frame>630 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour</title>
            <description>Participants will be randomly assigned by study statistician to treatment or placebo groups at a ratio of 3:1 following a double-blind placebo controlled food challenge, DBPCFC1, on 2 separate days. One challenge will consist of 5 doses of peanut in increasing amounts up to a total of 443 mg of peanut protein masked in vehicle food. The second day will consist of placebo material given similarly. Participants with an eliciting dose of 443mg or less will receive daily escalating dosages of peanut flour OIT in a blinded fashion, as described in the modified rush phase, until a daily dose of 4000 mg is reached. Following treatment, a 2nd challenge will occur DBPCFC2, identical to DBPCFC1, but with additional doses of 1000 mg and 3000 mg for a cumulative dose of 4443 mg peanut protein. After 12 weeks of complete peanut avoidance, participants will undergo a third challenge, DBPCFC3, which will follow a slightly different schedule of doses for a cumulative dose of 4430 mg peanut protein.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Oat) Flour</title>
            <description>Participants in the placebo arm will follow the same protocol except they receive daily escalating dosages of placebo oat flour, and they will not participate in DBPCFC3. Following DBPCFC2, assignment will be unblinded and placebo participants will be offered open-label active treatment under a separate protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical: Safety</title>
          <description>- The rate of reported adverse advents due to accidental ingestions in the active versus placebo groups.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mechanistic: TCR Clonal Diversity</title>
        <description>The change in the TCR clonal diversity of in vitro allergen-expanded Treg cells and induced Treg cells measured by TCRB CDR3 sequence clonotyping of sorted cells during active treatment among participants who achieve increased clinical tolerance (Tolerance and Partial Tolerance Groups as defined in clinical endpoints) versus the Treatment Failure Group.&#xD;
We conducted a nested case-control analysis of a subset of actively treated (by treatment outcome) versus placebo treated patients. Genomic DNA was used to amplify and sequence the complementarity-determining region 3 (CDR3) regions (immunoSEQ assay; Adaptive Biotechnologies).&#xD;
Enriched clonotypes in the CD154+ fraction (doi: https://doi.org/10.1101/2020.05.11.088286) were analyzed for differences by Rank Abundance Curve analysis (R package alakazam; Chao A, et al. Ecology. 2015 96, 11891201) to determine differences in clonal diversity.</description>
        <time_frame>630 days</time_frame>
        <population>We conducted a nested case-control analysis of a subset of actively treated (by treatment outcome) versus placebo treated patients. Genomic DNA was used to amplify and sequence the complementarity-determining region 3 (CDR3) regions (immunoSEQ assay; Adaptive Biotechnologies). Enriched clonotypes in the CD154+ fraction (doi: https://doi.org/10.1101/2020.05.11.088286) were analyzed for differences by Rank Abundance Curve analysis (R package alakazam; Chao A, et al. Ecology. 2015 96, 11891201).</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour -- Tolerance</title>
            <description>Tolerance: Ingestion of 4430 mg of peanut protein at DBPCFC3 without symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Peanut Flour -- Partial Tolerance</title>
            <description>Partial Tolerance: ED at DBPCFC3 &lt;4430 mg but 430 mg AND &gt;10-fold more than at DBPCFC1.</description>
          </group>
          <group group_id="O3">
            <title>Peanut Flour -- Treatment Failure</title>
            <description>Treatment Failure: Inability to tolerate the minimum maintenance dose (600 mg) of peanut protein by 12 months, or an ED &lt;1443 mg at DBPCFC2, or ED at DBPCFC3 &lt;443 mg OR &lt;10-fold more than at DBPCFC1</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (Oat Flour) treated participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanistic: TCR Clonal Diversity</title>
          <description>The change in the TCR clonal diversity of in vitro allergen-expanded Treg cells and induced Treg cells measured by TCRB CDR3 sequence clonotyping of sorted cells during active treatment among participants who achieve increased clinical tolerance (Tolerance and Partial Tolerance Groups as defined in clinical endpoints) versus the Treatment Failure Group.&#xD;
We conducted a nested case-control analysis of a subset of actively treated (by treatment outcome) versus placebo treated patients. Genomic DNA was used to amplify and sequence the complementarity-determining region 3 (CDR3) regions (immunoSEQ assay; Adaptive Biotechnologies).&#xD;
Enriched clonotypes in the CD154+ fraction (doi: https://doi.org/10.1101/2020.05.11.088286) were analyzed for differences by Rank Abundance Curve analysis (R package alakazam; Chao A, et al. Ecology. 2015 96, 11891201) to determine differences in clonal diversity.</description>
          <population>We conducted a nested case-control analysis of a subset of actively treated (by treatment outcome) versus placebo treated patients. Genomic DNA was used to amplify and sequence the complementarity-determining region 3 (CDR3) regions (immunoSEQ assay; Adaptive Biotechnologies). Enriched clonotypes in the CD154+ fraction (doi: https://doi.org/10.1101/2020.05.11.088286) were analyzed for differences by Rank Abundance Curve analysis (R package alakazam; Chao A, et al. Ecology. 2015 96, 11891201).</population>
          <units>percentage of clones</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010499258" lower_limit="0.0061792665" upper_limit="0.014819249"/>
                    <measurement group_id="O2" value="0.003841910" lower_limit="0.0011267402" upper_limit="0.006557080"/>
                    <measurement group_id="O3" value="0.003090797" lower_limit="0.0007072315" upper_limit="0.005474362"/>
                    <measurement group_id="O4" value="0.003592776" lower_limit="0.0009671402" upper_limit="0.006218412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mechanistic: Change Eliciting Dose of End-point Dilution.</title>
        <description>The change in eliciting dose of end-point dilution skin testing between actively treated and placebo treated participants following maintenance therapy and the change in ED of end-point dilution skin testing among actively treated participants following maintenance therapy and avoidance between clinical outcome groups.</description>
        <time_frame>518 days</time_frame>
        <population>skin test quality was poor</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour</title>
            <description>Participants will be randomly assigned by study statistician to treatment or placebo groups at a ratio of 3:1 following a double-blind placebo controlled food challenge, DBPCFC1, on 2 separate days. One challenge will consist of 5 doses of peanut in increasing amounts up to a total of 443 mg of peanut protein masked in vehicle food. The second day will consist of placebo material given similarly. Participants with an eliciting dose of 443mg or less will receive daily escalating dosages of peanut flour OIT in a blinded fashion, as described in the modified rush phase, until a daily dose of 4000 mg is reached. Following treatment, a 2nd challenge will occur DBPCFC2, identical to DBPCFC1, but with additional doses of 1000 mg and 3000 mg for a cumulative dose of 4443 mg peanut protein. After 12 weeks of complete peanut avoidance, participants will undergo a third challenge, DBPCFC3, which will follow a slightly different schedule of doses for a cumulative dose of 4430 mg peanut protein.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Oat) Flour</title>
            <description>Participants in the placebo arm will follow the same protocol except they receive daily escalating dosages of placebo oat flour, and they will not participate in DBPCFC3. Following DBPCFC2, assignment will be unblinded and placebo participants will be offered open-label active treatment under a separate protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanistic: Change Eliciting Dose of End-point Dilution.</title>
          <description>The change in eliciting dose of end-point dilution skin testing between actively treated and placebo treated participants following maintenance therapy and the change in ED of end-point dilution skin testing among actively treated participants following maintenance therapy and avoidance between clinical outcome groups.</description>
          <population>skin test quality was poor</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mechanistic: Change in Basophil Eliciting Dose.</title>
        <description>The change in peanut-specific basophil ED in actively treated participants at the end of maintenance and the end of avoidance between clinical outcome groups.</description>
        <time_frame>630 days</time_frame>
        <population>basophil time points inadequate for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour</title>
            <description>Participants will be randomly assigned by study statistician to treatment or placebo groups at a ratio of 3:1 following a double-blind placebo controlled food challenge, DBPCFC1, on 2 separate days. One challenge will consist of 5 doses of peanut in increasing amounts up to a total of 443 mg of peanut protein masked in vehicle food. The second day will consist of placebo material given similarly. Participants with an eliciting dose of 443mg or less will receive daily escalating dosages of peanut flour OIT in a blinded fashion, as described in the modified rush phase, until a daily dose of 4000 mg is reached. Following treatment, a 2nd challenge will occur DBPCFC2, identical to DBPCFC1, but with additional doses of 1000 mg and 3000 mg for a cumulative dose of 4443 mg peanut protein. After 12 weeks of complete peanut avoidance, participants will undergo a third challenge, DBPCFC3, which will follow a slightly different schedule of doses for a cumulative dose of 4430 mg peanut protein.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Oat) Flour</title>
            <description>Participants in the placebo arm will follow the same protocol except they receive daily escalating dosages of placebo oat flour, and they will not participate in DBPCFC3. Following DBPCFC2, assignment will be unblinded and placebo participants will be offered open-label active treatment under a separate protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanistic: Change in Basophil Eliciting Dose.</title>
          <description>The change in peanut-specific basophil ED in actively treated participants at the end of maintenance and the end of avoidance between clinical outcome groups.</description>
          <population>basophil time points inadequate for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mechanistic: Change in Peanut Allergen-specific IgG4</title>
        <description>The change in peanut allergen-specific IgG4 in actively treated participants by the end of maintenance between clinical outcome groups.</description>
        <time_frame>518 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour</title>
            <description>Participants will be randomly assigned by study statistician to treatment or placebo groups at a ratio of 3:1 following a double-blind placebo controlled food challenge, DBPCFC1, on 2 separate days. One challenge will consist of 5 doses of peanut in increasing amounts up to a total of 443 mg of peanut protein masked in vehicle food. The second day will consist of placebo material given similarly. Participants with an eliciting dose of 443mg or less will receive daily escalating dosages of peanut flour OIT in a blinded fashion, as described in the modified rush phase, until a daily dose of 4000 mg is reached. Following treatment, a 2nd challenge will occur DBPCFC2, identical to DBPCFC1, but with additional doses of 1000 mg and 3000 mg for a cumulative dose of 4443 mg peanut protein. After 12 weeks of complete peanut avoidance, participants will undergo a third challenge, DBPCFC3, which will follow a slightly different schedule of doses for a cumulative dose of 4430 mg peanut protein.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Oat) Flour</title>
            <description>Participants in the placebo arm will follow the same protocol except they receive daily escalating dosages of placebo oat flour, and they will not participate in DBPCFC3. Following DBPCFC2, assignment will be unblinded and placebo participants will be offered open-label active treatment under a separate protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanistic: Change in Peanut Allergen-specific IgG4</title>
          <description>The change in peanut allergen-specific IgG4 in actively treated participants by the end of maintenance between clinical outcome groups.</description>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.664" spread="0.559"/>
                    <measurement group_id="O2" value="0.375" spread="0.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mechanistic: Significant Gene Expression Changes by Transcriptional Profiling of Regulatory and Effector T Cell Populations</title>
        <description>Statistically significant gene expression changes (as number of genes) by transcriptional profiling of regulatory and effector T cell populations before and after OIT between clinical outcome groups.&#xD;
Total RNA from CD154+ and CD154-CD69- T cells was used for cDNA synthesis and amplification. Libraries were prepared and sequenced to a read depth of approximately 30 million reads per sample (Illumina HiSeq) and aligned to the hg19 human reference genome with the ensemble version 75 annotation using STAR version 2.5.3a,(Dobin et al. Bioinformatics 2013) and gene expression was summarized using RSEM version 1.3.0 (Li et al. BMC Bioinform 2013). Differential expression analysis was performed using DESeq2 v 1.30.1 (R v 4.04). Significance level was set at an unadjusted P value less than .001.</description>
        <time_frame>630 days</time_frame>
        <population>Subjects as defined per protocol. All 5 placebo were 'treatment failure -- non-desensitized' and per protocol, none were eligible for avoidance or DBPCFC3.&#xD;
Total RNA from CD154+ and CD154-CD69- T cells was used for cDNA synthesis and amplification. Read depth of approximately 30 million per sample (Illumina HiSeq) and aligned to the hg19 human reference genome with the ensemble version 75 annotation. Differential expression analysis was performed using DESeq2 v 1.30.1 (R v 4.04).</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Flour - Tolerance</title>
            <description>Tolerance: Ingestion of 4430 mg of peanut protein at DBPCFC3 without symptoms.</description>
          </group>
          <group group_id="O2">
            <title>Peanut Flour - Treatment Failure</title>
            <description>Treatment Failure: Inability to tolerate the minimum maintenance dose (600 mg) of peanut protein by 12 months, or an ED &lt;1443 mg at DBPCFC2, or ED at DBPCFC3 &lt;443 mg OR &lt;10-fold more than at DBPCFC1.</description>
          </group>
          <group group_id="O3">
            <title>Peanut Flour - Partial Tolerance</title>
            <description>Partial Tolerance: ED at DBPCFC3 &lt;4430 mg but 430 mg AND &gt;10-fold more than at DBPCFC1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Treatment Failure</title>
            <description>Received oat flour (placebo) treatment. All treatment failures; 3 due to early withdraw, 8 by DBPCFC2 outcome. Per protocol, none advanced to DBPCFC3.</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanistic: Significant Gene Expression Changes by Transcriptional Profiling of Regulatory and Effector T Cell Populations</title>
          <description>Statistically significant gene expression changes (as number of genes) by transcriptional profiling of regulatory and effector T cell populations before and after OIT between clinical outcome groups.&#xD;
Total RNA from CD154+ and CD154-CD69- T cells was used for cDNA synthesis and amplification. Libraries were prepared and sequenced to a read depth of approximately 30 million reads per sample (Illumina HiSeq) and aligned to the hg19 human reference genome with the ensemble version 75 annotation using STAR version 2.5.3a,(Dobin et al. Bioinformatics 2013) and gene expression was summarized using RSEM version 1.3.0 (Li et al. BMC Bioinform 2013). Differential expression analysis was performed using DESeq2 v 1.30.1 (R v 4.04). Significance level was set at an unadjusted P value less than .001.</description>
          <population>Subjects as defined per protocol. All 5 placebo were 'treatment failure -- non-desensitized' and per protocol, none were eligible for avoidance or DBPCFC3.&#xD;
Total RNA from CD154+ and CD154-CD69- T cells was used for cDNA synthesis and amplification. Read depth of approximately 30 million per sample (Illumina HiSeq) and aligned to the hg19 human reference genome with the ensemble version 75 annotation. Differential expression analysis was performed using DESeq2 v 1.30.1 (R v 4.04).</population>
          <units>number of differentially expressed genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>genes up at maintenance versus baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>genes up at avoidance versus baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="NA">not evaluable per protocol</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>genes down at maintenance versus baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="154"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>genes down at avoidance versus baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="NA">not evaluable per protocol</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>August 2013 to January 2016 (2 years and 5 months)</time_frame>
      <desc>Build up AEs, At home AEs, DBPCFC2 AEs</desc>
      <group_list>
        <group group_id="E1">
          <title>Peanut Flour</title>
          <description>Oral Immunotherapy with peanut flour.&#xD;
Peanut Flour: Peanut Flour</description>
        </group>
        <group group_id="E2">
          <title>Oat Flour</title>
          <description>Oral Immunotherapy with oat flour.&#xD;
Oat Flour: Oat Flour</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation, unrelated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Build up AEs; Moderate to severe AEs reported</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea/Vomting</sub_title>
                <description>Build up AEs; Moderate to severe AEs reported</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>At home AEs; Moderate to severe AEs reported</description>
                <counts group_id="E1" events="17" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <description>At home AEs; Moderate to severe AEs reported</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <description>DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <description>DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <description>Build up AEs; Moderate to severe AEs reported</description>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <description>At home AEs; Moderate to severe AEs reported</description>
                <counts group_id="E1" events="89" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin/oral pruritis</sub_title>
                <description>DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <description>DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <description>At home AEs; Moderate to severe AEs reported</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wheeze/SOB</sub_title>
                <description>DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <description>At home AEs; Moderate to severe AEs reported</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Angiodema</sub_title>
                <description>DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wayne Shreffler</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-6147</phone>
      <email>WSHREFFLER@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

